FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091508714> ?p ?o ?g. }

• W3091508714 abstract "Background Despite advances in the development of novel strategies against acute myeloid leukemia (AML), treatment options are limited and most patients relapse. Relapse occurs due to the persistence of chemotherapy-resistant leukemic stem cells (LSCs), which re-initiate the outgrowth of the disease, highlighting the need of targeting LSCs to improve patient survival. LSCs are characterized by the expression of the interleukin-3 receptor α, also known as CD123. CD123 is expressed on AML blasts and LSCs, and shows a moderate expression on normal hematopoietic stem cells, claiming CD123 as a suitable target antigen. CD47 is a ubiquitously expressed immune checkpoint upregulated on LSCs where it acts as an immune escape mechanism. CD47 transmits a ‘don’t eat me’ signal upon its interaction with the signal regulatory protein alpha (SIRPα) receptor on macrophages, thus inhibiting phagocytosis. In order to efficiently eliminate LSCs, we have designed a bifunctional antibody that specifically targets CD123 and simultaneously blocks CD47. Importantly, our strategy restricts the benefits of the CD47 blockade to CD123 + AML cells. Thus, we hypothesize a lower risk for on-target off-leukemia toxicity. Materials and Methods The bifunctional SIRPα-CD123 antibody was generated by fusing an extracellular domain of the SIRPα receptor, which functions as the CD47 blocking domain, to the CD123 antibody. The biological activity of the SIRPα-CD123 antibody was examined using AML-derived MOLM-13 cells, primary AML patient material and patient-derived xenografted (PDX) AML cells with NOD.Cg-Prkdc scid IL2rg tm1Wjl /SzJ (NSG) mice. Results The SIRPα fusion improved the binding of the bifunctional SIRPα-CD123 antibody to AML cells compared to a conventional CD123 antibody. The SIRPα-CD123 antibody enhanced the elimination of the AML-derived MOLM-13 cells by antibody-dependent cellular cytotoxicity via NK cells. Additionally, the cytotoxicity was confirmed using primary patient-derived AML cells. Furthermore, an improved cytotoxicity towards leukemia initiating AML PDX cells was observed with the SIRPα-CD123 antibody using luciferase bioluminescence in vivo imaging. With regards to the inhibition of CD47 signaling, we were able to show a blockade of CD47 on CD123 + CD47 + cells by the SIRPα-CD123 antibody. Correspondingly, a significant increase in phagocytosis of primary patient-derived AML cells mediated by monocyte-derived macrophages was observed in both allogenic and autologous setting. We were also able to show a preferential binding to MOLM-13 in the presence of a 20-fold excess of red blood cells indicating a potential low on-target off-leukemia toxicity. Conclusions The bifunctional SIRPα-CD123 fusion antibodies target the CD123+CD47+ cells and stimulate their phagocytosis by blocking the inhibitory CD47 signal. The dual mode of action of the SIRPα-CD123 has the potential to deplete the AML LSCs through NK cell cytotoxicity and macrophage-mediated phagocytosis while restricting the CD47 related on-target off-leukemia toxicity. Support H2020-EU grant agreement no 641549 Disclosure Information S. Tahk: None. S.M. Schmitt: None. B. Vick: None. C. Augsberger: None. L. Pascual Ponce: None. I. Jeremias: None. G. Wittmann: None. M. Subklewe: None. N.C. Fenn: None. K. Hopfner: None." @default.
• W3091508714 created "2020-10-08" @default.
• W3091508714 creator A5003069482 @default.
• W3091508714 creator A5011492039 @default.
• W3091508714 creator A5020923289 @default.
• W3091508714 creator A5029544187 @default.
• W3091508714 creator A5055416042 @default.
• W3091508714 creator A5056400412 @default.
• W3091508714 creator A5059567988 @default.
• W3091508714 creator A5061922466 @default.
• W3091508714 creator A5073217077 @default.
• W3091508714 creator A5086659894 @default.
• W3091508714 date "2020-10-01" @default.
• W3091508714 modified "2023-09-26" @default.
• W3091508714 title "P09.12 Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells" @default.
• W3091508714 doi "https://doi.org/10.1136/jitc-2020-itoc7.112" @default.
• W3091508714 hasPublicationYear "2020" @default.
• W3091508714 type Work @default.
• W3091508714 sameAs 3091508714 @default.
• W3091508714 citedByCount "0" @default.
• W3091508714 crossrefType "journal-article" @default.
• W3091508714 hasAuthorship W3091508714A5003069482 @default.
• W3091508714 hasAuthorship W3091508714A5011492039 @default.
• W3091508714 hasAuthorship W3091508714A5020923289 @default.
• W3091508714 hasAuthorship W3091508714A5029544187 @default.
• W3091508714 hasAuthorship W3091508714A5055416042 @default.
• W3091508714 hasAuthorship W3091508714A5056400412 @default.
• W3091508714 hasAuthorship W3091508714A5059567988 @default.
• W3091508714 hasAuthorship W3091508714A5061922466 @default.
• W3091508714 hasAuthorship W3091508714A5073217077 @default.
• W3091508714 hasAuthorship W3091508714A5086659894 @default.
• W3091508714 hasBestOaLocation W30915087141 @default.
• W3091508714 hasConcept C104317684 @default.
• W3091508714 hasConcept C109159458 @default.
• W3091508714 hasConcept C123894998 @default.
• W3091508714 hasConcept C159654299 @default.
• W3091508714 hasConcept C203014093 @default.
• W3091508714 hasConcept C2778461978 @default.
• W3091508714 hasConcept C2778729363 @default.
• W3091508714 hasConcept C2780104668 @default.
• W3091508714 hasConcept C28328180 @default.
• W3091508714 hasConcept C40767141 @default.
• W3091508714 hasConcept C502942594 @default.
• W3091508714 hasConcept C55493867 @default.
• W3091508714 hasConcept C71924100 @default.
• W3091508714 hasConcept C83396363 @default.
• W3091508714 hasConcept C86803240 @default.
• W3091508714 hasConcept C95444343 @default.
• W3091508714 hasConceptScore W3091508714C104317684 @default.
• W3091508714 hasConceptScore W3091508714C109159458 @default.
• W3091508714 hasConceptScore W3091508714C123894998 @default.
• W3091508714 hasConceptScore W3091508714C159654299 @default.
• W3091508714 hasConceptScore W3091508714C203014093 @default.
• W3091508714 hasConceptScore W3091508714C2778461978 @default.
• W3091508714 hasConceptScore W3091508714C2778729363 @default.
• W3091508714 hasConceptScore W3091508714C2780104668 @default.
• W3091508714 hasConceptScore W3091508714C28328180 @default.
• W3091508714 hasConceptScore W3091508714C40767141 @default.
• W3091508714 hasConceptScore W3091508714C502942594 @default.
• W3091508714 hasConceptScore W3091508714C55493867 @default.
• W3091508714 hasConceptScore W3091508714C71924100 @default.
• W3091508714 hasConceptScore W3091508714C83396363 @default.
• W3091508714 hasConceptScore W3091508714C86803240 @default.
• W3091508714 hasConceptScore W3091508714C95444343 @default.
• W3091508714 hasLocation W30915087141 @default.
• W3091508714 hasOpenAccess W3091508714 @default.
• W3091508714 hasPrimaryLocation W30915087141 @default.
• W3091508714 hasRelatedWork W12592135 @default.
• W3091508714 hasRelatedWork W13566098 @default.
• W3091508714 hasRelatedWork W14256629 @default.
• W3091508714 hasRelatedWork W14516486 @default.
• W3091508714 hasRelatedWork W5069414 @default.
• W3091508714 hasRelatedWork W683509 @default.
• W3091508714 hasRelatedWork W740184 @default.
• W3091508714 hasRelatedWork W767785 @default.
• W3091508714 hasRelatedWork W8514342 @default.
• W3091508714 hasRelatedWork W860291 @default.
• W3091508714 isParatext "false" @default.
• W3091508714 isRetracted "false" @default.
• W3091508714 magId "3091508714" @default.
• W3091508714 workType "article" @default.